American Association for Cancer Research
10559965epi170367-sup-182559_1_supp_4057712_8qtxky.pdf (218.41 kB)

Supplemental Table 1 from History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Download (218.41 kB)
journal contribution
posted on 2023-03-31, 13:50 authored by Albina N. Minlikeeva, Jo L. Freudenheim, Kevin H. Eng, Rikki A. Cannioto, Grace Friel, J. Brian Szender, Brahm Segal, Kunle Odunsi, Paul Mayor, Brenda Diergaarde, Emese Zsiros, Linda E. Kelemen, Martin Köbel, Helen Steed, Anna deFazio, Susan J. Jordan, Peter A. Fasching, Matthias W. Beckmann, Harvey A. Risch, Mary Anne Rossing, Jennifer A. Doherty, Jenny Chang-Claude, Marc T. Goodman, Thilo Dörk, Robert Edwards, Francesmary Modugno, Roberta B. Ness, Keitaro Matsuo, Mika Mizuno, Beth Y. Karlan, Ellen L. Goode, Susanne K. Kjær, Estrid Høgdall, Joellen M. Schildkraut, Kathryn L. Terry, Daniel W. Cramer, Elisa V. Bandera, Lisa E. Paddock, Lambertus A. Kiemeney, Leon F.A.G. Massuger, Rebecca Sutphen, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A. Gayther, Susan J. Ramus, Aleksandra Gentry-Maharaj, Celeste L. Pearce, Anna H. Wu, Jolanta Kupryjanczyk, Allan Jensen, Penelope M. Webb, Kirsten B. Moysich

Description of the studies included in the pooled analysis and methods of data collection





U.S. Army Medical Research and Materiel Command

National Health & Medical Research Council of Australia

American Cancer Society

National Institute for Health Research University College London Hospitals Biomedical Research Centre

Polish Ministry of Science and Higher Education



Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470–3. ©2017 AACR.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention



    Ref. manager